Purple Biotech

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC

Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting

REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the year and the six months ended December 31, 2021.

Purple Biotech Reports Second Half and Full-Year 2021 Financial Results

REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, is pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders.

Purple Biotech Issues Letter to Shareholders

REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Ori Hershkovitz, a long-time life sciences industry investor, to its Board of Directors.

Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors

REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Fabien Sebille, Ph.D., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its Chief Business Officer. Dr. Sebille, who has led a series of licensing deals in oncology over the last four years, will be primarily responsible for business development, including strategic partnering opportunities.

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX ® ), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal Adenocarcinoma

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program

REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 12:20 pm GMT. The conference will take place from November 16 - 19, 2021. Management will be available for one-on-one meetings.

Purple Biotech to Present at the Jefferies London Healthcare Conference

Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST. The conference will take place from June 1 – June 4, 2021. Management will be available for one-on-one meetings.

Purple Biotech to Present at the Jefferies Virtual Healthcare Conference

Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted

Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors.

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors

Preliminary Data from First Part of Study Anticipated in Second Half of 2021

Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients

TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, were presented in a poster entitled "Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2," at the American Association of Cancer Research (AACR) 2021 Annual Meeting. These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center.

Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting

Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb

Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers

TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, will be presented in a poster at the American Association of Cancer Research (AACR) 2021 Annual Meeting, taking place in virtual format, on April 10-15 and May 17-21, 2021.  These updated data expand on the previously reported results generated from the Company's collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center, and will be highlighted in a presentation titled, “Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2.”

Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting

Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Robert Gagnon to its Board of Directors. Mr. Gagnon has 15 years of experience in corporate finance and commercial operations, much of it in the biotech industry. Purple Biotech's Board of Directors now includes seven members, five of whom are independent directors. Mr. Gagnon shall serve as a member of the first class of the Board of Directors until the annual general meeting of shareholders to be held in 2022, at which time he may stand for reelection.

Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors

Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company. The post PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge appeared first on InvestorPlace.

PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge

Kitov Pharma

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech management team will present a corporate overview at the B. Riley Oncology Investor Conference, being held virtually January 20-21, 2021.

Purple Biotech to Present at the B. Riley Oncology Investor Conference

Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech

News for Purple Biotech Stock (PPBT)